Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA | BSE: 524715) has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, offering a novel treatment option for adults suffering from Erosive Esophagitis of all grades. FEXUCLUE® is a next-generation potassium-competitive acid blocker (PCAB) that introduces a new therapeutic class in the Indian market.

The drug is being introduced under a licensing agreement with Daewoong Pharmaceutical Co. Ltd., Korea, which grants Sun Pharma the rights to manufacture and commercialize FEXUCLUE® in India. As part of the agreement, Daewoong will receive upfront payments, milestone-based payments, and royalties.

Speaking on the launch, Kirti Ganorkar, CEO – India Business, Sun Pharma, said,

“Erosive Esophagitis significantly impacts patients’ quality of life, and existing treatments don’t always meet clinical needs. FEXUCLUE® offers a best-in-class option that has the potential to fill this treatment gap. At Sun Pharma, we continue to prioritize innovative solutions that improve patient outcomes.”

Fexuprazan’s efficacy and safety were established in a Phase 3, double-blind, double-dummy clinical trial conducted among adult Indian patients. The study’s primary goal was to assess healing of Erosive Esophagitis, confirmed via endoscopy. The trial successfully met its endpoint, with over 95% of participants achieving healing within eight weeks, and the drug demonstrated a favorable safety profile.